What is this study trying to find out about bone loss and osteoporosis risk?

This study is evaluating how advanced imaging devices can measure bone and muscle structure to better understand fracture risks linked to osteoporosis and related conditions. Researchers aim to improve fracture risk prediction beyond current methods like DEXA scanning. The study is led by the Centre Hospitalier Universitaire de Saint Etienne and focuses on bone microarchitecture changes across various diseases.

Who may be eligible for this osteoporosis risk clinical trial?

Adults aged 18 and older who have an increased risk of osteoporosis due to factors like brittle bone fractures, inflammatory joint diseases, chronic kidney disease, endocrinopathies, or neurological disorders may be eligible. Both men and women can participate. People currently taking certain bone-affecting medications or without signed consent are excluded. Please review eligibility criteria for more details.

Is there any cost to participate in this bone loss clinical trial?

Study-related care, including the imaging tests with HR-pQCT, pQCT, and DEXA and all trial visits, is provided at no cost. Personal travel expenses or other costs may vary and are not guaranteed to be covered. Participants should consider these factors when deciding about joining.

Actively Recruiting

Phase Not Applicable

Age: 18Years +

All Genders

ID06541548

Comparison of Bone Microarchitecture Analysed by High Resolution Peripheral Microscanner HR-pQCT and Peripheral Microscanner pQCT in Pathologies With Bone Loss andor Muscle Loss

Led by Centre Hospitalier Universitaire de Saint Etienne · Updated on 2026-03-03

1000

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Researchers are evaluating bone and muscle microarchitecture using advanced medical devices to better understand fracture risks linked to conditions such as osteoporosis, rheumatoid arthritis, neurological disorders, and other related pathologies. This study highlights the limits of current methods like DXA scanning and aims to provide deeper insights into structural changes like cortical porosity and trabecular volume loss, which are important in diseases like post-menopausal osteoporosis and sarcopenia. The research also focuses on how conditions like renal insufficiency and endocrinopathies affect bone health and includes a control group to distinguish disease effects from normal aging changes. The study uses devices including the Xtreme CT HR-pQCT, peripheral quantitative computed tomography pQCT, and Lunar DEXA. These devices will measure bone density and architecture at various body sites such as the forearm, shin, and metacarpophalangeal joints, especially in patients with rheumatoid arthritis. Participants are divided into groups at risk for osteoporosis and those not at risk, with bone quality and quantity described using these imaging technologies. The assessments occur on a single day for each participant. Participants will undergo detailed imaging tests with HR-pQCT, pQCT, and DEXA to measure various bone parameters such as volumetric mineral density, trabecular thickness, cortical porosity, and bone mineral content. These measures will help describe bone strength and structure in relation to different diseases. The study is non-randomized and open-label, with results expected to improve fracture risk estimation and inform management strategies. The total participation time primarily involves the initial imaging assessments, and safety monitoring is inherent in the non-invasive procedures used.

CONDITIONS

Brief Title

Comparison of Bone Microarchitecture Analysed by HRpQCT and pQCT in Pathologies With Bone Loss and/or Muscle Loss

Who Can Participate

Age: 18Years +

All Genders

Eligibility Criteria

You may qualify if you...

Adults aged 18 years or older
Women or men treated at Saint-Etienne University Hospital with risk factors for osteoporosis
History of brittle bone fracture or bone fragility requiring bone densitometry
Diagnosed with inflammatory joint diseases such as rheumatoid arthritis or spondyloarthritis
Diagnosed with chronic kidney disease or endocrinopathies including primary hyperparathyroidism, constitutional thinness, anorexia nervosa, obesity (BMI >30), or sarcopenia
Diagnosed with neuropathies such as Parkinson's disease
Control group participants with an acute episode of spinal or radiculalgia less than one month old and corticosteroid treatment less than one month
Signed written consent

You will not qualify if you...

No signed written consent
For control group: use of medications inducing bone loss including anti-aromasin or GnRH agonists for at least 6 months
Use of corticosteroids at doses equal or greater than 5 mg/day for 6 months or more
Use of anti-epileptic drugs such as carbamazepine, phenobarbital, phenytoin, primidone, or valproic acid for at least 6 months
History of fracture due to bone fragility
Currently taking bone-targeting medications including bisphosphonates, teriparatide, or strontium ranelate

Research Team

Hubert MAROTTE, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here